Most recently, the discovery that certain METex14 mutations are potential drivers of disease in NSCLC, exhibiting sensitivity to treatment with MET-inhibitor therapy, has led to renewed interest in MET as a targetable biomarker. The gene discussed is MET; the disease is non-small cell lung carcinoma.